BOSTON–AcuityMD has partnered with Channel Medsystems to support the commercial relaunch of Cerene Endometrial Cryotherapy, a minimally invasive treatment for heavy menstrual bleeding, using artificial intelligence to identify healthcare providers and expand patient access.
The Boston-based healthcare technology company said its AcuityAI platform helped Channel Medsystems revise its marketing and commercial strategy after the medical device manufacturer experienced limited physician engagement during Cerene’s initial launch.
Cerene is a non-hormonal, incision-free treatment that uses cryotherapy to reduce heavy menstrual bleeding, a condition affecting approximately one in five women in the United States.
The treatment is designed to provide an alternative to conventional approaches, including hormonal therapies and heat-based endometrial ablation.
Channel Medsystems initially focused its commercial efforts on physicians who primarily performed traditional heat-based ablation procedures.
However, the company found that this approach was limiting its ability to reach healthcare providers who might be interested in offering cryotherapy as an alternative treatment.
Using AcuityMD’s artificial intelligence platform, Channel Medsystems analyzed market data to identify different physician groups, prioritize geographic markets, and refine its commercial outreach strategy.
“We scrubbed the word ‘ablation’ from everything, and completely rebranded all commercial materials to focus strictly on the differentiators and advantages of cryotherapy. It’s a different technology that preserves access to the uterine cavity,” said Tara Murphy, Vice President of Marketing at Channel Medsystems.
“And we leaned into AcuityAI to help us identify the right target physicians, prioritize markets with the largest opportunity, and strategically expand our field team with better customer segmentation.”
Following the revised commercial strategy, Channel Medsystems reported increases in new customer accounts, repeat orders, and quarter-over-quarter business growth.
The companies did not disclose specific percentage increases or revenue figures associated with those improvements.
AcuityMD’s platform uses industry-specific healthcare data to help medical technology companies identify potential customers, evaluate market opportunities, and improve their commercial operations.
The company said more than 500 medical technology businesses use its platform.
“Since relaunching Cerene using AcuityMD’s AI platform to develop a refreshed customer segmentation strategy, we have made meaningful progress increasing physician engagement and building awareness of a differentiated treatment option for women suffering from heavy menstrual bleeding and dysmenorrhea,” Murphy said.
“Our progress continues with AcuityMD’s Salesforce integration as we can easily import target lists into Salesforce as leads.”
Channel Medsystems is also using prescription data incorporated into AcuityAI to identify physicians who prescribe hormonal birth control to patients experiencing heavy menstrual bleeding.
The company believes this information could help it reach healthcare providers whose patients may be interested in learning about non-hormonal treatment options.
However, prescription patterns alone cannot determine whether individual patients are appropriate candidates for Cerene treatment.
The partnership also played a role in Channel Medsystems’ financing activities.
According to the company, market data generated through AcuityAI helped demonstrate its commercial strategy and growth potential to investors.
Channel Medsystems announced in August 2026 that it had raised $30 million in its ongoing Series C financing round.
“AcuityMD provided the right data to validate and back our claims to investors and instill confidence for our future success,” Murphy said. “We showed investors that we are making decisions guided by industry-specific data, and that all came from AcuityMD.”
The collaboration highlights the growing use of artificial intelligence in the medical device industry, particularly in commercial planning, market analysis, and identifying healthcare providers who may benefit from information about new treatment technologies.
AcuityMD is scheduled to discuss the role of AI in accelerating the adoption of medical technologies during the HLTH 2026 conference in Las Vegas on November 17.
The presentation will focus on how medical technology companies can use data-driven strategies to improve commercial operations and bring treatment options to patients more efficiently.


